


Participant Flow Chart



Baseline Characteristics

	Total (N=12)
Sex	
Male	12 (100%)
N	12
Race	
White	11 (92%)
Asian or Asian British	1 (8%)
N	12
Age	
N	12
Mean	30
SD	9.3
Median	26
Min	20
Max	48
Height (m)	
N	12
Mean	1.79
SD	0.05
Median	1.78
Min	1.69
Max	1.87
Weight(kg)	
N	12
Mean	79.8
SD	11.31
Median	77.30
Min	65.20
Max	99.10
BMI (kg/m ²)	
N	12
Mean	24.9
SD	3.09
Median	24.27
Min	20.81
Max	29.77

Outcomes Measured

Treatment	A	B	C	C
Dosage form	size 0 capsule with ~14mg PC	size 2 capsule with ~6mg PC	size 2 capsule with ~8mg PC	size 2 capsule with ~8mg PC
Fasted/Fed Dosed	Fed N = 12	Fed N = 12	Fed N = 12	Fasted N = 12
Site of onset				
Stomach	0 (0 %)	3 (25 %)	1 (8.3 %)	1 (8.3 %)
Jejunum	3 (27.3 %)	7 (58.3 %)	6 (50 %)	5 (41.7 %)
Jejunum/Ileum	4 (36.4 %)	2 (16.7 %)	4 (33.3 %)	3 (25 %)
Ileum	4 (36.4 %)	0 (0 %)	1 (8.3 %)	3 (25 %)
N	11	12	12	12
Onset radiolabel release [min]				
Mean	253.9	202.1	266.3	93.3
SD	47.33	68.97	44.78	70.8
Median	242.5	212.5	262.5	65
Min - Max	182.5 - 327.5	102.5 - 352.5	197.5 - 347.5	32.5 - 237.5
N	11	12	12	12

Adverse Events

Total participants n = 12	
Number of participants with at least one AE	6 (50%)
Total number of AEs	7
Number of participants with at least one TEAE	6 (50%)
Total number of TEAEs	7
Total number of participants with at least one SAE	0 (0%)
Total number of SAEs	0
Total AEs n =7	
Total number of treatment related AEs	3 (42.9%)
Total number of AEs leading to death	0 (0%)
Total number of AEs leading to discontinuation	0 (0%)
Intensity Grading	
Mild	7
Moderate	0
Severe	0